Abselion

Abselion, founded in 2017 and headquartered in the United Kingdom, is at the forefront of simplifying protein research. Their mission is encapsulated in their slogan: "Protein research made simple." The company operates within the Biotechnology industry, focusing on providing tools to accelerate biotherapeutics development. Through their proprietary Redox Electrochemical Detection (RED) technology, the award-winning Amperia system offers a novel approach to biologics and viral-vector quantification, allowing for automated, cost-effective titre measurement.

Abselion's technology emphasizes high automation and minimal hands-on time, empowering scientists to focus on innovative bioprocess optimization. Their dynamic team, blending biology, nanotechnology, and data science, thrives in a flat hierarchy fostering idea-sharing and passion. As of their last investment on 20 April 2021, Abselion secured a £1.90M Seed Round backed by investors like Parkwalk Advisors, New Ground Ventures, University of Cambridge Enterprise, Swiss Health Angels, and R42 Group.